A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Study Identifier:

SEP361-124

ClinicalTrials.gov Identifier:

NCT05402111

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

Schizophrenia

Study Drug

Drug: SEP-363856
Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)

Date

Jun 2022 - Sep 2023

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

A clinical study to determine whether an investigational medication (SEP363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia. This study is accepting both male and female subjects. It will be conducted in approximately 6 study sites in the United States. The duration of participation will be approximtely 10 weeks.

Study Locations

Location

Status

Location

Woodland International Research Group

Little Rock, Arkansas, United States, 72211

Status

N/A

Location

Woodland Research Northwest, LLC

Rogers, Arkansas, United States, 72758

Status

N/A

Location

Collaborative Neuroscience Research, LLC

Long Beach, California, United States, 90806

Status

N/A

Location

CNRI - San Diego, LLC

San Diego, California, United States, 92102

Status

N/A

Location

Galiz Research

Hialeah, Florida, United States, 33016

Status

N/A

Location

Research Centers of America

Oakland Park, Florida, United States, 33334

Status

N/A